Endometriosis - Opportunity Analysis and Forecasts to 2017 - WDAM.COM - TV 7 - News, Weather and Sports

Endometriosis - Opportunity Analysis and Forecasts to 2017

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE M/S. Reportstack

NEW YORK, BERLIN, PARIS and LONDON, February 4, 2014 /PRNewswire/ --

Reportstack has announced a newly published market intelligence report on Endometriosis - Opportunity Analysis and Forecasts to 2017 which forecasts that global endometriosis therapeutics sales to grow slowly to $1.2bn at a compound annual growth rate (CAGR) of 0.19%.  GnRH antagonists dominate the late-stage pipeline for endometriosis therapeutics, with three agents being in Phase II or Phase III (Neurocrine/AbbVie's elagolix, Takeda's relugolix, and Astellas' ASP-1707). Elagolix, which is in Phase III, promises to be the first oral GnRH antagonist approved for endometriosis. This class of therapies has several key advantages over the currently marketed GnRH agonists. In terms of safety and tolerability, elagolix avoids the hormonal flare, and detrimental hypoestrogenic side effects seen with GnRH agonists such as Lupron and Zoladex.

According to key opinion leaders (KOLs) interviewed by GlobalData, an oral formulation will be a welcome addition to the field that provides doctors with increased control over dosing and allows for the immediate cessation of therapy, if necessary. This improved therapeutic profile will allow GnRH antagonists to command premium over GnRH agonists. Ultimately, while this new class of drugs will undoubtedly displace the incumbent GnRH therapies, their high price tag will limit their penetration in other patient segments - especially given the low cost of oral contraceptives and progestins.

The KOLs agree- patients with endometriosis have significant unmet needs due to the lack of continuously efficacious therapies with favorable long-term safety. Moreover, significant gaps in the current understanding of the underlying disease pathology remains a hurdle plaguing therapeutic development. Although doctors are optimistic about late-stage pipeline therapies, they foresee that unmet needs will persist after these products are launched. Ultimately, since none of the drugs on the horizon are curative, significant opportunity will remain for safe, efficacious therapies that target the root cause of the condition.

The report estimates that the global endometriosis therapeutics market in the 6MM was valued at $1.88 billion in 2012. The market was largely dominated by the US, with sales of $1.1 billion. Combined sales in the 5EU were estimated at $137.6m. By 2017, the authoring publisher forecasts that global sales of endometriosis therapeutics will decrease slowly to $1.66 billion at a CAGR of 0.19%. The list of companies which are considered for this market analysis are Astellas, Astra Zeneca, Balonco, Bayer, ElexoPharm, Euroscreen, Evestra, Evotec,  Forendo Pharma, Kissei, Lipicard, Neurocrine, Orphagen, Pfizer, QuatRX, Sanofi, SK Chemicals, Takeda, Teva, ValiRX and Warner Chilcott.

Reasons to Buy    

•    Overview of endometriosis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines

•    Annualized endometriosis therapeutics market revenue, annual cost of therapy, and top line US and 5EU market forecasts from 2012 to 2017

•    Key topics covered include: strategic competitor assessment, market characterization, unmet needs, and implications for the endometriosis therapeutics market

•    Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs

•    Analysis of the current and future market competition in the global endometriosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

To view the detailed table of contents of this report kindly visit - Endometriosis - Opportunity Analysis and Forecasts report .

Other Opportunity Analysis and Market Forecasts Reports:

OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2017

OpportunityAnalyzer: Acute Ischemic Stroke - Opportunity Analysis and Forecasts to 2017

OpportunityAnalyzer: Uveitis - Opportunity Analysis and Forecasts to 2017

OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017

OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) - Opportunity Analysis and Forecasts to 2017

About Reportstack™:

Reportstack.com is one of the leading distributors of market research reports in the world today. Reportstack.com provides access to over 50,000 company profiles and their strategic information like SWOT analysis, deals and partnerships analysis, merger & acquisition activity and new product launches. Reportstack.com is also a leader in the field of Pharma partnership deals and competitor analysis & Medical Devices Market Research Reports.

Contact Reportstack.com:

Nathan Gold

Phone: +1 888-789-6604

Email: nathan@reportstack.com

Follow us: https://twitter.com/reportstack



Pharma Reports: http://www.reportstack.com/category/11/pharma-healthcare-market-research-reports.html

Contact: Nathan Gold, +1-888-789-6604

©2012 PR Newswire. All Rights Reserved.